EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyse

FGF21 Analogues in Patients With Metabolic Diseases: Systematic Review and Meta‐Analysis of Randomised Controlled Trials

Panagiotis Theofilis iD, Evangelos Oikonomou iD, Paschalis Karakasis, Konstantinos Pamporis, Kyriakos Dimitriadis iD, Eleni Kokkou, Vaia Lambadiari, Gerasimos Siasos, Konstantinos Tsioufis, Dimitris Tousoulis

Liver International · 2025

DOI: 10.1111/liv.70016 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Liver International, 2025. Verfasst von Panagiotis Theofilis und 9 weiteren Autor:innen. Beteiligte Einrichtung: 1st Department of Cardiology, "Hippokration" General Hospital, National and Kapodistrian University of Athens, Athens, Greece. Hauptthemen laut MEDLINE: Fibroblast Growth Factors, Metabolic Diseases, Liver Cirrhosis, Fatty Liver. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 42 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims Liver‐related complications are frequent in patients with metabolic diseases, with limited treatment options currently available. This systematic review and meta‐analysis aimed to assess the effect of fibroblast growth factor‐21 (FGF21) analogues on hepatic steatosis, inflammation and fibrosis in patients with metabolic diseases.

Methods

We conducted a systematic literature search in Pubmed, Scopus and Web of Science for randomised controlled trials (RCTs) assessing the effect of FGF21 analogues on hepatic steatosis evaluated by hepatic fat fraction (HFF), inflammation and fibrosis compared to placebo. Adverse events (AEs) were also recorded.

Results

Treatment with FGF21 analogues was associated with metabolic‐associated steatohepatitis (MASH) resolution without fibrosis worsening (5 studies, risk ratio [RR] 4.40, 95% confidence interval [CI]: 2.41, 8.03, p < 0.001) and fibrosis improvement by 1 grade without MASH worsening (6 studies, RR 1.79, 95% CI: 1.24, 2.59, p = 0.002). FGF21 analogues significantly lowered HFF compared to placebo (6 studies, SMD ‐1.08, 95% CI: −1.28, −0.88, p < 0.001), while patients receiving FGF21 analogues were more likely to exhibit a reduction in HFF by 30% (10 studies, RR 4.08, 95% CI: 3.08, 5.40, p < 0.001) or 50% (6 studies, RR 10.43, 95% CI: 5.47, 19.87, p < 0.001). HFF normalisation (≤ 5%) was more frequently achieved with FGF21 analogues (6 studies, RR 14.58, 95% CI: 4.70, 45.18, p < 0.001). The results remained robust after sensitivity analyses. Serious AE and AE leading to drug discontinuation were similar in patients receiving FGF21 analogues or placebo.

Conclusions

FGF21 analogues can reduce hepatic steatosis, inflammation and fibrosis in patients with metabolic diseases, representing a possible treatment option for steatotic liver disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Fibroblast Growth FactorsMetabolic DiseasesLiver CirrhosisFatty LiverNon-alcoholic Fatty Liver DiseaseHumansRandomized Controlled Trials as Topic

Stichwörter der Autor:innen

fibroblast growth factor 21hepatic fat fractionhepatic fibrosissteatohepatitis

Substanzen

Fibroblast Growth Factorsfibroblast growth factor 21FGF21 protein, human

Autor:innen und Institutionen

  • 1st Department of Cardiology, "Hippokration" General Hospital, National and Kapodistrian University of Athens, Athens, Greece.
  • 3rd Department of Cardiology, Thoracic Diseases General Hospital "Sotiria", National and Kapodistrian University of Athens, Athens, Greece.
  • 2nd Department of Cardiology, Hippokration General Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.
  • Second Department of Internal Medicine, Attikon University Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
  • Cardiovascular Division, Harvard Medical School, Brigham and Women's Hospital, Boston, Massachusetts, USA.

ORCID-Profile: Panagiotis Theofilis, Evangelos Oikonomou, Kyriakos Dimitriadis

Zitieren

APA

Theofilis, P., Oikonomou, E., Karakasis, P., Pamporis, K., Dimitriadis, K., Kokkou, E., Lambadiari, V., Siasos, G., Tsioufis, K., & Tousoulis, D. (2025). FGF21 Analogues in Patients With Metabolic Diseases: Systematic Review and Meta‐Analysis of Randomised Controlled Trials. Liver International. https://doi.org/10.1111/liv.70016

Vancouver

Theofilis P, Oikonomou E, Karakasis P, Pamporis K, Dimitriadis K, Kokkou E, et al. FGF21 Analogues in Patients With Metabolic Diseases: Systematic Review and Meta‐Analysis of Randomised Controlled Trials. Liver International. 2025. doi:10.1111/liv.70016

BibTeX
@article{Theofilis2025,
  author = {Theofilis, Panagiotis and Oikonomou, Evangelos and Karakasis, Paschalis and Pamporis, Konstantinos and Dimitriadis, Kyriakos and Kokkou, Eleni and Lambadiari, Vaia and Siasos, Gerasimos and Tsioufis, Konstantinos and Tousoulis, Dimitris},
  title = {FGF21 Analogues in Patients With Metabolic Diseases: Systematic Review and Meta‐Analysis of Randomised Controlled Trials},
  journal = {Liver International},
  year = {2025},
  doi = {10.1111/liv.70016}
}
Kostenlos starten →